HIV Pathogenesis: Dynamics and Genetics of Viral Populations and Infected Cells by Coffin, John & Swanstrom, Ronald
HIV Pathogenesis: Dynamics and Genetics
of Viral Populations and Infected Cells
John Coffin1 and Ronald Swanstrom2
1Department of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts 02111
2Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599
Correspondence: john.coffin@tufts.edu
In the absence of treatment, HIV-1 infection, usually starting with a single virion, leads inex-
orably to a catastrophic decline in the numbers of CD4þ T cells and to AIDS, characterized by
numerous opportunistic infections as well as other symptoms, including dementia and
wasting. In the 30 years since the AIDS pandemic came to our attention, we have learned
a remarkable amount about HIV-1, the responsible virus—the molecular details about
how it functions and interacts with the host cell, its evolution within the host, and the counter-
measures it has evolved to overcome host defenses against viral infection. Despite these
advances, we remain remarkably ignorant about how HIV-1 infection leads to disease and
the death of the human host. In this brief article, we introduce and discuss important
lessons that we have learned by examining the dynamics of viral populations and infected
cells. These studies have revealed important features of the virus–host interaction that now
form the basis of our understanding of the importance and consequence of ongoing viral rep-
lication during HIV-1 infection.
TIME COURSE OF INFECTION
As discussed elsewhere (Shaw and Hunter2011), HIV-1 infection is usually initiated
with a single virion infecting a single target
cell at the portal of entry. The subsequent course
of infection can be monitored in several ways:
overt symptoms, such as fever, wasting, op-
portunistic infections, neurological symptoms,
and so on; blood levels of the CD4þ T-cell tar-
get and antiviral antibodies; and viremia (virus
in blood), measured by infectivity, immunoas-
say for viral proteins, and, most accurately, by
PCR for viral RNA. A typical time course of in-
fection relating these properties to one another
is shown in Figure 1. Although their timing can
vary considerably from individual to individ-
ual, as can the levels of viremia, the general out-
line is essentially the same in virtually every
infected person who does not receive effective
antiviral therapy.
1. (1–2 wk) An eclipse phase, during which
the virus is freely replicating and spreading
from the initial site of infection to the
many tissues and organs that provide the
sites for replication. Viremia is undetectable,
and neither immune response nor symp-
toms of infection are yet visible.
2. (2–4 wk) The acute (or primary) infection
phase, characterized by relatively high levels
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of viremia (up to 107 or more copies of viral
RNA per milliliter of blood), and large frac-
tions of infected CD4þ T cells in blood and
lymph nodes. This phase is often, but not
always, accompanied by “flu-like” symp-
toms—fever, enlarged lymph nodes, and
the like. Around the time of peak viremia,
the immune response begins to appear,
both in the form of antibodies against all
viral proteins, and a CD8þ T-cell response
against HIV-1 antigens expressed on infected
cells. The high levels of viremia that charac-
terize this phase most likely result from the
absence of the early immune response and
the generation, as part of the host response,
of large numbers of activated CD4þ T cells,
providing a wealth of targets for viral replica-
tion. At the end of the acute phase, the level
of viremia declines sharply, 100-fold or
more, a result of both partial control by the
immune system and exhaustion of activated
target cells. This phase is also characterized
by a transient decline in the numbers of
CD4þ T cells in the blood.
3. (1–20 yr) Chronic infection, or “clinical
latency,” is characterized by a constant or
slowly increasing level of viremia, usually
on the order of 1–100,000 copies/mL,
sometimes referred to as the “set point,”
and steady, near normal (1000 cells/mL),
or gradually falling levels of CD4þ T cells.
As a rule, patients in this phase are asympto-
matic and usually unaware that they have
been infected. Despite the term “latency,”
the viral infection is far from latent, with
large numbers of CD4þ T cells becoming
infected and dying every day.
4. Finally, the number of CD4þ T cells declines
to the point (200 cells/mL) at which
immune control of adventitious infectious
agents can no longer be maintained, and
opportunistic infections (discussed in Lack-
ner et al. 2011) begin to appear. Control of
the HIV-1 infection itself is also lost, and
the level of viremia rises during the AIDS
phase, culminating in death of the infected
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Figure 1. Time course of typical HIV infection. Patterns of CD4þT cell decline and viremia vary greatly from one
patient to another. (From Fauci and Desrosiers 1997; reprinted, with permission, from Cold Spring Harbor Lab-
oratory Press # 1997.)
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is one of the most uniformly lethal infectious
diseases known, with a mortality rate well
over 95%.
SIGNIFICANCE OF VIREMIA
As clinical researchers were developing tools for
diagnosis and prognosis of HIV-1 infection, it
became apparent that the most powerful of
them is the measurement of viremia using
quantitative nucleic acid hybridization or PCR
assays for HIV-1 genomic RNA in blood. RNA
measurements have the virtue of an extraordi-
narily wide dynamic range. Routine commer-
cial assays can now accurately measure levels
of viremia as low as 50 copies/mL and as high
as 107 or more copies/mL. More sensitive re-
search assays have reduced the lower end to
much less than 1 copy/mL with good quantita-
tive accuracy (Palmer et al. 2003).
The first recognition of the prognostic
importance of viremia came from analysis of a
large prospective study of gay men at risk for
AIDS, the Multicenter AIDS Cohort Study
(MACS), in which volunteers provided blood
samples and health information at frequent
intervals over long periods of time, during
which many men who were initially infected,
but still healthy, progressed to AIDS and death
(Mellors et al. 1996). When the levels of viremia
at study entry were compared with outcome, a
strong inverse correlation between the level of
viremia and the time of progression to AIDS
was observed (Fig. 2). The data showed that
the group with the highest level of viremia pro-
gressed to AIDS on average about fourfold faster
than the lowest group. Thus, the level of virus
present in the blood provides a measure of
the rate at which viral infection damages the
immune system of the infected host.
The second important insight made possi-
ble by the ability to accurately measure levels
of viremia was in analyzing the consequences
of antiviral therapy, where it was found that
the ability of an antiretroviral drug to halt or
even reverse progression of an infected patient
to AIDS was well correlated with its ability to
suppress viremia. Effective therapies, such as
combinations of antiviral drugs discussed by
Arts and Hazuda (2011), which can lead to sus-
tained reductions in viremia to undetectable
levels of ,50 copies/mL by standard clinical
assays, can forestall progression to AIDS indef-
initely, although they do not cure the infection.
Indeed, if therapy is suspended, even after many
years, the level of viremia will rapidly return to
the prior set point.
The correlation between viremia and disease
has a straightforward underlying explanation
(Coffin 1995). Infected cells produce virions,
some fraction of which are released into the
blood, from which they are rapidly removed or
degraded. Although different cells may produce

















































Figure 2. Relationship between viral load (viremia) and clinical progression. Shown are Kaplan–Meier plots of
AIDS-free survival divided into quartiles according to virus load (A) or CD4 count (B) at the time of diagnosis.
(From Fauci and Desrosiers 1997; reprinted, with permission, from Cold Spring Harbor Laboratory Press
# 1997.)
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blood, their numbers are very large, and, on
average, the amount of virus per infected cell
will be about the same from time to time in
the same patient and similar from one patient
to another. Also, the rate of removal of virions
from the blood will be similar (and, as has
been measured, quite rapid) from time to
time and patient to patient. Because the level
of viremia is determined by the balance between
virion release into and removal from the blood-
stream, assuming a constant rate of release per
cell and a constant rate of removal, the level of
viremia will be an instantaneous relative meas-
ure of the number of productively infected cells
at any one time.
INSIGHTS FROM THERAPEUTIC
DRUG STUDIES
This understanding of the significance of vire-
mia in HIV-1 infection, combined with the
new availability of potent antiretroviral drugs
(Arts and Hazuda 2011), led to an experiment
that provided considerable insight into the
process of HIV-1 infection and pathogenesis
in vivo (Fig. 3) (Coffin 1995; Ho et al. 1995;
Wei et al. 1995). The study was based on the
principle that all antiviral drugs affect the abil-
ity of the virus to infect cells and do not affect
the lifetime of infected cells or their ability to
produce viral particles (albeit noninfectious
ones in the case of protease inhibitors). There-
fore, any decrease in viremia following initiation
of suppressive therapy must reflect a combina-
tion of the length of time that productively
infected cells live and produce virus after infec-
tion and the lifetime of the virus in the blood.
Because the latter factor is very small, it can be
ignored with little effect on the overall result.
Thus, viremia was assayed by quantitative PCR
at closely spaced time points after initiation of
suppressive therapy, with striking results: After
a brief lag, viremia drops rapidly, to 1%–
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Figure 3. Decay of circulating virus and infected cells after initiation of suppressive antiviral therapy. These
results imply the presence of at least four classes of HIV-infected cells: productively infected, a second class, per-
haps macrophages, with a half-life of 2 wk; latently infected resting CD4 cells, with a half-life of 6 mo; and
long-lived DNA positive cells, most of which are nonproductive. A fourth class of infected cells, inferred to have
an approximately infinite half-life, is not shown. (Figure modified from Fauci and Desrosiers 1997.)
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1–2 d. Following this first phase of decay,
there is a second phase in which most of the
remaining viremia decays with a half-time of
2 wk or so, down to the detection limit of
standard assays. Two more phases, which have
been defined with more sensitive assays, are dis-
cussed below.
The first phase of decay almost certainly
reflects the lifetime of productively infected
CD4þ T cells, although the exact cells and their
location have not been identified. The second
phase has been speculatively attributed to mac-
rophages (Perelson et al. 1997), but this point is
far from established. Given that this phase is
much less prominent when the treatment
includes an integrase inhibitor, it may reflect
at least in part a population of infected cells in
which integration is delayed for some reason
(Murray et al. 2007).
THE HIV-1 STEADY STATE
The results discussed above, combined with the
fact that the characteristic level of viremia (set
point) in any infected individual is essentially
constant, led to the conclusion that HIV-1 exists
in the infected host as a quasi-steady state, in
which the level of viremia is largely determined
by the number of virus-producing cells, which
therefore must also be constant day in and day
out throughout most of the course of infection.
In any given patient, therefore, there are about
the same number of infected cells today as there
were yesterday and last year, but they must be
different cells arising from infection of fresh
target cells, which then rapidly die after pro-
ducing sufficient virus, on average, to infect
the same number of cells again. This concept
is key to our current understanding of the
HIV–host interaction. It has many important
implications.
1. The replication cycle time of the virus is, on
average, 1–2 d. Thus, virus in an individ-
ual at a year after infection is 200–300 gener-
ations removed from the initial infecting
virion.
2. The population size is determined by the
steady-state number of productively infected
cells, not by the number of virions, except
that the latter must be at least large enough
to ensure that the same number of cells is
infected every day.
3. The steady state is remarkably robust, chang-
ing little throughout the clinically latent
phase, and returning to the same value after
even prolonged periods (7 yr or more) when
it is undetectable on suppressive therapy, or
after transient increases due to immune
stimulation by vaccination or by infection
with some other agent.
4. The virus exists as a replicating population
that is carried forward by repeated infection
of large numbers of cells with no evidence of
bottlenecks or other major alterations in
population size from time to time.
5. The level of viremia is determined by a com-
bination of the number of available target
cells, the infectivity of the virus, the number
of virions produced per cell, the productive
lifetime of the infected cell, and the clearance
rate of the virus.
6. We know little about the infected cells that
are responsible for producing the virus
observed in the blood and can only infer
their properties indirectly.
7. The extraordinary extent of genetic diversity
that accumulates during HIV-1 infection,
relative to other RNA viruses, is not due to
its unusually high error rate, but rather to
replication of a large population of virus
with an average error rate repeated over and
over again, accumulating thousands of gen-
erations over the course of infection of a sin-
gle individual.
With these properties in mind, we can look
at some specific issues.
Nature and Lifetimes of Infected Cells
The initial therapeutic studies that led to the
steady-state concept implied two populations
of target cells: one with a half-life of 1–2 d
and another of 2 wk. These conclusions
generated considerable optimism because the
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proportionality of the level of viremia to the
number of productively infected cells suggested
that sufficiently prolonged treatment could
eventually reduce the number of infected cells
to ,1, effectively curing the patient of the
HIV-1 infection. Unfortunately, these hopes
were dashed when further studies, using more
sensitive techniques, revealed the presence of
at least two more phases of decay of HIV-1 vir-
emia on fully suppressive therapy, apparently
due to small populations of infected cells capa-
ble of surviving and releasing virus many years
after infection (Siliciano and Green 2011).
Although such cells constitute only a tiny frac-
tion of the total number of infected cells present
before therapy, they decay very slowly (with a
half-life of 6 mo by one estimate) (Zhang
et al. 1999) after treatment. Also, much more
sensitive PCR assays, with a limit of detection
well below 1 copy/mL of viral RNA in plasma
(Palmer et al. 2003), revealed that the majority
patients on therapy with “undetectable” vire-
mia for more that 1 yr in fact had an average
of about 3 copies of HIV-1 RNA per milliliter,
or about 1/10,000 of the level before therapy,
and that this level declined further with a curve
consistent with two more phases of decay: one
with a half-life of 39 wk, not significantly
different from that of inducible cells, perhaps
from the same source, and another with a half-
life not different from infinity, suggesting
the possibility of a dividing reservoir. Viremia
was still detectable in all patients as long as 7
yr after the start of therapy (Palmer et al.
2008). The existence of these populations of
cells, apparently infected before therapy and
capable of producing virus many years later,
rules out eradicating infection by antiviral ther-
apy alone.
One more population of infected cells bears
discussion. In a typical chronically infected
individual, about one CD4þ T cell per 100 to
one per 1000 contains HIV-1 DNA, largely in
the form of an integrated provirus. Very few cells
contain more than one provirus (Josefsson et al.
2011). After the initiation of therapy, there is an
initial decline in the numbers of these cells,
reflecting the decay in viremia and implying
that at least some of the virus in the blood comes
from populations of cells also found in the
blood. However, as can be seen in Figure 3,
the level of viral DNA positive cells soon levels
off, typically somewhere around 1%–10% of
the starting value, implying that a significant
fraction of these cells is not involved in phase
1 or 2 viral production. Furthermore, the num-
bers of DNA positive cells after prolonged
therapy is typically 100-fold greater than the
number of cells inducible to produce virus ex
vivo (Chun et al. 1997), implying that most of
them are incapable of ever producing infectious
virus, perhaps because of mutations in the pro-
virus, unfavorable sites of integration, or some
undefined cellular factor that prevents expres-
sion of the silent provirus. Simple modeling
implies that over time, because of their much
longer lifetime, cells containing inactive or
latent proviruses should accumulate to a con-
siderable extent relative to productively infected
cells, most of which die within a few days. Thus,
only a small fraction of the population of cells
containing detectable proviruses represent cells
that are latently infected, that is, that contain a
provirus that is not expressed but is capable of
being induced to express infectious virus by
some means, such as stimulation to reenter
the cell cycle. For this reason, it cannot be
assumed (although it often is) that the nature
of cells in the so-called latent reservoir pre-
sumed responsible for the persistence of HIV-
1 during years of therapy can be inferred from
the properties of all provirus-containing cells
(such as sites of integration, expression of tran-
scription factors, etc.), the large majority of
which must contain dead proviruses incapable
of reincarnation. The physical identification
and manipulation of the tiny fraction of latently
infected cells in suppressed infection is a major
unsolved problem in HIV-1 pathogenesis (Mal-
darelli 2011; Siliciano and Green 2011).
Persistence of HIV-1 Infection on Therapy
Although it is well accepted that the large
majority of patients on suppressive therapy
have low levels of viremia as well as latently
infected cells capable of being reactivated to
produce HIV-1 ex vivo, the link between the
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two phenomena remains somewhat controver-
sial, with some investigators arguing that the
persistent viremia observed in patients on long-
term therapy could also be due to a small
amount of “escape” replication of virus in ana-
tomic sites or cells that are poorly accessible to
antiviral therapy (referred to as “sanctuaries”)
(Sharkey and Stevenson 2001). In support of
this claim, they point to the ongoing presence
of two-LTR circles (Craigie and Bushman
2011) in PBMCs in a fraction of patients (Buzon
et al. 2011), an observation interpreted as
meaning that productive infection of new cells
is continuing to occur. However, the underlying
assumption that the circular forms of viral DNA
are inherently unstable in cells in vivo remains
unsupported, and there are several lines of evi-
dence in favor of the idea that the low-level vir-
emia observed in the majority of patients on
long-term suppressive therapy is derived from
cells infected before the start of treatment.
1. The distribution of the levels of viremia
among treated patients is independent of
the drugs used for treatment (Maldarelli
et al. 2007). This result is not what would
be expected for replication in a sanctuary
because it is improbable that such sites or
cells would be equally unavailable to differ-
ent drugs.
2. The level of viremia is not affected by the
inclusion of another drug. Several studies
have been performed in which a suppressive
three-drug regimen was intensified by the
addition of a fourth inhibitor of a class previ-
ously unseen by the patient (Dinoso et al.
2009; Gandhi et al. 2010; McMahon et al.
2010). Despite some differences in design
and inhibitors used, all studies gave the
same result: There was no difference in the
amount of virus during and after the intensi-
fication period as compared with before.
Again, it is highly improbable that sanctuaries
of replication would be equally inaccessible to
all drugs, and these results are inconsistent
with low-level ongoing replication.
3. As is discussed in more detail in the next sec-
tion, accumulation of genetic variation due
to the rapid turnover of infected cells is a
hallmark of HIV-1 infection. In the chronic
infection phase, there is a slow but percepti-
ble turnover of the viral population such that
genetically distinct populations arise every
few years (F Maldarelli, M Kearney, S Palmer,
et al., unpubl.). In contrast, in patients on
maximally suppressive therapy, evolution of
viral genomes is frozen at the point at which
therapy began (Ruff et al. 2002; Tobin et al.
2005), and no evidence for continuing evo-
lution can be seen even after many years. In
patients for which therapy is partially sup-
pressive, ongoing evolution can still be
observed (Tobin et al. 2005), as is also true
in patients known as “elite controllers,” who
naturally control HIV-1 infection at levels
similar to those seen in patients on suppres-
sive antiviral therapy (Mens et al. 2010). The
apparent lack of evolution on therapy is
consistent with the absence of new cycles of
infection.
4. As noted, the appearance of 2-LTR circles in a
minority of patients undergoing intensifica-
tion with an integrase inhibitor raises the
possibility of a low level of infection occur-
ring in the face of antiviral drugs. However,
this result remains to be fully understood
or reproduced.
5. It has recently been suggested, on the basis of
mathematical and cell culture modeling, that
the high multiplicity of infection that would
result from cell–cell spread could greatly
reduce the effectiveness of antiviral therapy
and allow persistent viral replication (Sigal
et al. 2011). However, this model predicts
that cells infected in vivo should have multi-
ple proviruses and that genetic variation
should continue to accrue on suppressive
therapy, neither of which is observed.
Regarding point 2, in the small amount of
virus in the blood of some patients whose vire-
mia has been suppressed for more than 3 yr or
so, significant subpopulations of virus with
genomes identical in sequence can be observed
and, in some cases, can become a large fraction
of the total population (Bailey et al. 2006).
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These subpopulations have been called pre-
dominant plasma clones (PPCs). Their origin
is unknown, but it can be speculated that they
may arise from a very small fraction of infected
cells that is capable of dividing and releasing
virus but that do not die as a result of the expan-
sion. Such clonal populations of virus can also
be seen in the blood of patients who have
stopped suppressive therapy after long-term
suppression (Joos et al. 2008), although the
two phenomena have not yet been firmly con-
nected. It seems likely that the last, apparently
stable, phase of viremia on therapy reflects clo-
nal viral populations, but this point remains to
be established.
It is important to keep in mind that the
infected cell populations that give rise to long-
lived, persistent viremia on therapy are not cre-
ated by the therapy; rather, they must exist
throughout the course of infection, only to be
exposed as the shorter-lived cells of phases 1
and 2 die off and are not replenished and the
virus produced by them disappears. The cells
responsible for the production of the persistent
virus must represent an extremely small fraction
of the total population of productively infected
cells in chronic infection—somewhere between
1024 and 1025 is a reasonable estimate. Given
that HIV-1 infection is carried forward, day in
and day out, by repeated cycles of infection,
viral production, and death of target cells, these
long-lived cell populations must be irrelevant to
the natural history of HIV-1 infection (as well as
SIV infection of the natural hosts). They are of
critical importance to attempts to treat HIV-1
infection, however, because the virus they pro-
duce is capable of rekindling full-blown infec-
tion from the faintest embers remaining after
prolonged completely suppressive therapy.
GENETIC VARIATION AND EVOLUTION
One of the first unusual features of HIV-1 infec-
tion to become apparent was the remarkable
accumulation of genetic diversity during the
course of infection of a single individual.
Indeed, when first observed, it represented the
fastest rate of evolution in any natural eukary-
otic system; for example, the extent of HIV-1
diversity that accumulates in one infected indi-
vidual exceeds that of all influenza virus isolates
worldwide in any given year (Korber et al.
2001). (Actually, the record diversity no longer
belongs to HIV, having since been eclipsed by
hepatitis C virus.) Although it was first thought
that the remarkable diversification reflected an
extraordinarily high underlying error rate asso-
ciated with HIV-1 replication, we now know
that this rate is about average for an RNA virus
and that it is the pace of replication, the dura-
tion of infection, and the size of the replicating
population, allowing it to evolve rapidly in
response to selective influences, that set HIV-1
(and HCV) apart from all other known viral
infections. These features, in addition to the
ease of generating large numbers of sequences
either directly from infected individuals and
populations of individuals with well-timed
infections or from massive databases of such
sequences (Kuiken et al. 2003), have made
HIV-1 a favorite topic of study for evolutionary
biologists, and they have used it effectively to
develop and test new mathematical models for
evolution in general, not just for HIV-1 or just
for viruses. We do not present any specific mod-
els here, but the next section discusses the role of
specific factors of evolution that all models
must include and how they apply to HIV-1 in
an infected human host.
Factors of HIV-1 Evolution
By “evolution,” we mean the process by which
genetic change accumulates during generations
of replication. For any replicating entity, or-
ganisms or viruses, the general principles of
evolution are similar, although their application
can differ greatly. As a rule, models are based on
consideration of four principal factors. We dis-
cuss them here in the context of HIV.
Mutation
In the case of HIV-1 and other retroviruses, mu-
tations are primarily attributed to error-prone
reverse transcription, but there are actually
two other possible sources of error: transcrip-
tion by host RNA polymerase II, and G-to-A
hypermutation mediated by ABOBEC3G (or
J. Coffin and R. Swanstrom



















F). As discussed in other articles in this col-
lection (Hu and Hughes 2011; Karn and Stoltz-
fus 2011; Malim and Bieniasz 2011), the relative
contribution of these mechanisms is a matter of
some debate. Whatever the source, the overall
single-step point mutation rate for HIV-1 is
3  1025 mutations per base per replication
cycle, and about 10-fold less for transversions
than transitions (Mansky and Temin 1995).
Thus, about one genome in three contains a
mutation after a single round of replication.
Other types of mutation, including frameshifts
(insertion or deletion of small numbers of
bases), as well as large-scale deletions, inser-
tions, duplications, and inversions, are also com-
mon (Svarovskaia et al. 2003). The error rate of
retrovirus replication, while much greater than
that of cellular and viral DNA polymerases, is
about average for RNA viruses.
Selection results from the ability of one var-
iant to replicate more effectively than another, a
property referred to as “fitness.” In the case of
viruses, fitness differences lead to differences
in the number of infectious progeny at each rep-
lication cycle. Fitness differences can result from
differences at any stage of the series of events
leading from one infected cell to the next,
including efficiency of entry, rate of infectious
progeny production by an infected cell, and its
productive lifetime, stability of the infectious
virion, and so on. Note that there is no such
thing as absolute fitness: The concept is mean-
ingful only in relative terms and only in a spe-
cific context (e.g., in vitro vs. in vivo, in the
presence or absence of neutralizing antibodies
or antiviral drugs). It is often expressed as a
selection coefficient, the difference in the rela-
tive number of progeny produced by one var-
iant compared with another per generation.
Thus, for a variant that yields 1% more in-
fectious progeny than another, the selection
coefficient is 0.01. For large populations under-
going multiple repeated cycles of infection, even
small selection coefficients can have major
effects on the frequency of slightly advanta-
geous or disadvantageous mutations, with the
former leading to positive selection and the
latter to purifying selection. Because synony-
mous mutations (those that do not change the
corresponding amino acid) generally have much
smaller selection coefficients than nonsynony-
mous ones, the ratio between the two in a pop-
ulation (dN/dS) is a useful indicator of the
nature of selective forces acting at any given
site or set of sites.
Drift
“Drift” is a term for the change in frequency of a
variant independent of selection or mutation,
resulting from sampling error that arises when
replicating population sizes are small. In the
case of viral populations, it is important to
bear in mind that the population size is deter-
mined by the number of cells infected at each
round of replication, not by the number of viri-
ons produced by them. In the case of HIV-1
infection, perhaps 1011 virions are produced
daily; the number of cells infected in the same
time span is still a matter of some debate, but
is unlikely to exceed 109. A further important
consideration is the effective population size:
in simple terms, the number of infected cells
multiplied by the probability that any one cell
gives rise to progeny that go on to infect other
target cells. If there is an infinite supply of target
cells and the population of infected and target
cells is well mixed, then the effective population
size can be similar to the census population size
(defined as the total number of infected cells).
These conditions obviously do not apply in
infected individuals, and the effective popula-
tion size is probably much smaller. At very large
effective population sizes, evolution can be con-
sidered to be deterministic, in that the fre-
quency of a mutation at any given time (in
generations) in the future can be exactly deter-
mined from its present frequency, mutation
rate, and selection coefficient, as long as these
factors remain constant. At smaller sizes, evolu-
tion becomes more and more stochastic, that is,
subject to random factors, so that the frequency
can only be predicted as an average, with the
variance increasing with decreasing size. A use-
ful relationship to keep in mind is that, after
many generations of deterministic evolution,
slightly deleterious mutations will reach an
equilibrium frequency equal to the mutation
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rate divided by their selection coefficient. In the
stochastic case, this calculation will give the
average value over many observations but will
vary considerably from one individual to the
next. This consideration is of more than aca-
demic interest because it defines the probability
that drug-resistance mutations, which are
slightly deleterious in the absence of the drug,
will already be present in the replicating viral
population before initiation of antiviral ther-
apy (the so-called genetic barrier) (see Arts
and Hazuda 2011). Although transition from
deterministic to stochastic evolution is continu-
ous with decreasing population size, a useful
approximate crossover point to keep in mind
is a size equal to the inverse of the mutation
rate, at which it becomes probable that all pos-
sible single mutations will arise at each round of
replication (Rouzine and Coffin 2005).
Linkage
To complicate matters further, selection does
not act on individual mutations, but rather on
whole genomes, which may contain other
mutations as well. In very large deterministic
populations, where any mutation is always
present in many genomes, this effect is unim-
portant; in smaller populations, it can prevent
selection from operating on individual muta-
tions, and even, in extreme cases (and at least
in theory) lead to declining fitness of a popula-
tion due to gradual accumulation of deleterious
mutations (Muller’s ratchet). Linkage can thus
be visualized as increasing the role of stochas-
tic effects on evolution, even at large population
sizes. The effect of linkage on evolution can be
reduced by recombination to allow mutations
to be redistributed among genomes. It is im-
portant to keep in mind that recombination
does not generate diversity, but rather redistrib-
utes it among replicating genomes, allowing
effects of selection to be felt more strongly. As
discussed elsewhere (Hu and Hughes 2011),
recombination between genetically distinct ge-
nomes in retrovirus replication occurs at very
high rates, but only during reverse transcription
of genomes from heterozygous progeny of cells
containing two or more proviruses. Although
it was originally reported that such multiply
infected cells are very frequent in HIV-infected
individuals (Jung et al. 2002), more recent
results suggest that they are much rarer, consti-
tuting perhaps 10% of infected CD4þ T cells
in blood (Josefsson et al. 2011). Nevertheless,
there is ample evidence for the occurrence and
importance of recombination in HIV-1 infec-
tion, particularly in rare individuals coinfected
with two or more genetically distinct viruses
(Keele et al. 2008; Kearney et al. 2009).
Course of Evolution following Infection
Monitoring of genetic diversity of the virus
following HIV-1 infection has provided a very
important tool for understanding many impor-
tant aspects of the virus–host interaction. For
reasons discussed above, the sequences of viral
genomes in the blood provide the most accurate
instantaneous indicator for the genetics of the
replicating viral population, particularly when
single-genome sequencing (SGS) technology,
which avoids many PCR artifacts (Palmer
et al. 2005), is used. Figure 4 shows, in cartoon
form, the important events in virus evolution
during the course of a “typical” infection, start-
ing with a clonal population and proceeding
toward the highly diverse populations charac-
teristic of chronic infection. The initial accumu-
lation of diversity is at a rate very close to the
mutation rate, with little evidence for selection,
except for highly deleterious mutations; as time
goes on, purifying selection takes hold, and the
increase in diversity begins to level off, ap-
proaching an asymptotic value of an average
pairwise distance 1%–2% for gag, pro, and
pol, which are largely subject to purifying selec-
tion, as indicated by low dN/dS ratios. Rates are
much higher for env, where the greater, and con-
stantly increasing, diversity and higher dN/dS
ratios point to constant positive selection result-
ing from an ever-changing antibody response
(Richman et al. 2003). In the case of gag, pro,
and pol (as well as accessory genes, particularly
nef ), even though dN/dS ratios are low, positive
selection can be discerned at sites correspond-
ing to T-cell epitopes. Indeed, virtually all of
the nonsynonymous diversity accumulating in
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these genes in untreated infection can be attrib-
uted to escape from the cytotoxic T-cell (CTL)
response (Kearney et al. 2009; Walker and
McMichael 2011). In env, escape from the anti-
body response is characterized not only by
point mutation, particularly affecting the dis-
play of glycosylation sites, but also by gross
structural changes—insertions and duplica-
tions—in the hypervariable loops V1, V2, and
V4, which tend to increase in length and num-
bers of glycosylation sites (the “glycan shield”)
during the course of infection. It is important
to bear in mind that, given the conditions under
which HIV populations are evolving, even weak
selective forces (on the order of a few percent)
can have dramatic effects on the genetics of
the viral population. Thus, it cannot be inferred
from these results alone that the immune re-
sponse plays a significant role in controlling
HIV infection. The partial control of viral
replication by the host is likely the sum of effects
of the immune response and the fitness cost
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Figure 4. Typical evolution of HIV after infection. (A) The level of viremia (orange) and the genetic diversity,
measured as the average pairwise difference (black) of the HIV population as a function of time after infection.
(B) Phylogenetic relationship of HIV-1 sequences at various stages of infection. The colored circles correspond
to sequences of plasma virus RNA sampled at the corresponding time points in A: At peak viremia (yellow),
the viral population (in most patients) is highly uniform, diversifying gradually over the first few years of
infection. Samples taken from chronic infection (green and blue) are considerably more diverse, but take 3
yr or more to diverge perceptibly (red). Following initiation of suppressive therapy, divergence ceases, even
after long times (orange, gray). After years of therapy, clonal populations of virus arise in some patients
(black).
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incurred with the initial escape by the virus, a
fitness cost that is in part alleviated over time
through compensatory mutations.
A remarkable aspect of HIV genetic diver-
sity during chronic infection is its stability.
Except in the case of escape from antiretroviral
therapy, genetic turnover of the viral population
in the blood is very slow, with no evidence of
a genetic or physical bottleneck (Shankarappa
et al. 1999; F Maldarelli, M Kearney, and S
Palmer, unpubl.). This observation is consistent
with a large replicating population that can be
steered by immune selection, but without ever
having to recover from significant depletion.
Because mutations leading to immune escape
will often reduce fitness, when that immune re-
sponse is not present, such as after transmission
to another person, these mutations will tend to
revert to the consensus sequence, although at
highly variable rates. For example, mutations
increasing the length of the variable loops tend
to reset to shorter length following transmission
(Shaw and Hunter 2011).
In addition to immune escape, resistance to
antiretroviral therapy is an important conse-
quence of genetic diversity accumulating during
chronic HIV-1 infection. Both theory (dis-
cussed above) and observation are consistent
with the idea that drug-resistance mutations
that accumulate to low levels before therapy
are an important cause of failure. Indeed, in vir-
tually all cases, treatment of HIV-1 infection
with a single agent (monotherapy) leads to rapid
reappearance of viremia, rebounding to levels
near the pretherapy set point. A striking exam-
ple is in women treated with a single dose of the
nonnucleoside RT inhibitor (NNRTI) nevira-
pine to prevent mother-to-child transmission
(Chersich and Gray 2005). A single pill taken
during labor prevents a significant fraction of
infections of the newborn but leads to a very
high frequency of drug-resistant virus in the
mother a few weeks later. The reproducibility
of this dramatic effect implies a low (and so
far undetectable) frequency of NNRTI-resistant
mutants in the replicating viral population
combined with a relatively long lifetime of the
drug, allowing their selection during the ensu-
ing cycles of HIV-1 replication.
Unlike the immune response, antiviral ther-
apy can impose a significant physical and genet-
ic bottleneck on the HIV-1 population, with
drug-resistant virus that rebounds after mono-
therapy often showing substantially less diver-
sity than the starting population (Kitrinos et al.
2005).
Another important consequence of HIV
genetic variation is the appearance of popula-
tions of virus infecting specific anatomical
compartments and cell types. As discussed
by Swanstrom and Coffin (2011), HIV can be
found in a large number of organs and tissues.
In some sites, such as the central nervous
system (CNS), there is a clear genetic separation
of independently evolving populations, often
leading to macrophage-tropic viruses that likely
replicate in either macrophages or microglial
cells in the brain. Macrophage-tropic viruses
can also be found late in infection at other
anatomical sites, but their pathophysiological
significance is much less clear. The final impor-
tant consequence of HIVevolution in vivo is the
appearance of virus capable of using alternative
coreceptors, such as CXCR4, distinct from the
CCR5 chemokine receptor used by the founder
virus.
HOW DOES HIV-1 CAUSE AIDS?
As is apparent from this article and the rest of
the collection, in the 25þ years since its dis-
covery, we have learned an enormous amount
about HIV, but we still cannot answer the one
big question: How does HIV-1 cause AIDS? At
first thought, the answer is obvious. HIV-1
infects and kills CD4þ T cells. AIDS is a result
of loss of CD4þ T cells. QED. Unfortunately, it
is not that simple.
For starters, although HIV-1 infection kills
infected cells ex vivo, by a mechanism that is still
controversial, there is still considerable debate
about how infected cells die in vivo. There are
three alternatives: virus-mediated killing of
infected cells, as in culture systems; immune-
mediated effects due to HIV-specific CD8þ
T cells or antibodies; or one or more of a variety
of indirect effects. In support of the role of such
direct killing is the short half-life of infected
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cells early in infection, before the appearance of
antibodies or CTL, ruling out the adaptive
immune response as essential for cell killing in
vivo. The innate (i.e., interferon) response
could still play some role at this point, however.
Although the antibody response appears to have
little effect on the life of the infected cell, there is
evidence for an important role of the CTL
response in cell killing because treatment of
SIV-infected macaques with antibody directed
against CD8 leads to a significant (100-fold)
but transient increase in the level of viremia
(Jin et al. 1999; Schmitz et al. 1999). The most
straightforward explanation for this result is
that CTLs shorten the productive lifetime of
the infected cell, although more indirect effects
have also been proposed (Davenport and Pet-
ravic 2010; Klatt et al. 2010; Wong et al. 2010).
Two features of this hypothesis are worth not-
ing. First, the productive lifetime of an infected
cell is the time from the onset of virus produc-
tion to cell death by CTL and is likely to be
not much shorter than the lifetime defined by
virus-mediated killing, perhaps only an hour
or so. Second, it is likely that part of the advant-
age conferred on HIV-1 (and other complex
viruses) by the two-step replication strategy
mediated by tat and rev is the delay of the syn-
thesis of virion proteins as long as possible in
the life cycle to minimize exposure to the CTL
response and maximize virion output per cell.
Although cells can die from the effects of infec-
tion alone, their productive lifetime is some-
what shortened by the CTL response, that is,
specifically during the time when virus is being
produced. Thus, CTLs can modulate infection,
but they do not eliminate it. Effects due to
immune activation could include not only deg-
radation of immune function late in infection,
but also stimulation of production of activated
memory CD4þ T cells, increasing the number
of targets available to the virus.
Even if we knew the mechanism of HIV-
mediated cell killing, we would not know how
HIV-1 causes CD4þ T-cell decline and AIDS
in humans. The observation that virus and cell
turnover rates in various SIVs in their natural
hosts (such as SIVsm in sooty mangabeys),
which do not progress to AIDS, are essentially
identical to those in humans, who do progress,
implies that cell killing alone cannot account
for AIDS pathogenesis. Indeed, this result is
consistent with the high natural turnover rate
of activated effector memory helper T cells,
the primary target for HIV-1 infection, on the
order of 1010 cells per day, of which only a small
fraction are infected after the initial primary
infection phase. Clearly, in the natural host,
these viruses have evolved to replicate in a pop-
ulation of cells that is replenished constantly
and in excess over what is needed for good
health. In unnatural hosts, such as HIV-1 infec-
tion of humans, or SIVsm infection of ma-
caques, something else must be happening to
lead to AIDS. Two features that distinguish the
pathogenic from nonpathogenic infection are
chronic immune activation, discussed above,
and greater levels of infection of other CD4þ
T-cell subsets, particularly central memory
helper T cells. The former may lead eventually
to immune exhaustion and damaged lymphoid
architecture, the latter (which might, itself, be a
result of immune activation) to loss of critical
cells necessary for maintenance of a diverse
response to common environmental pathogens.
Sorting out the roles of these and other side
effects of HIV-1 infection in the causation of
AIDS will provide subject matter for HIV-1
researchers for a long time to come.
SUMMARY AND PERSPECTIVE
Quantitation of viral RNA in plasma, of viral
DNA in cells, and of cells capable of being
stimulated to express quiescent proviruses has
led to a conceptual framework of the dynamics
of HIV-1 replication and persistence in the host.
The availability of suppressive antiviral therapy
has brought disease progression under control,
and it has also provided a means to perturb
the dynamics of viral replication that has
revealed additional features of viral persistence,
features that show the necessity for lifelong ther-
apy given the current treatment strategies. The
dynamic changes in the sequence of the viral
genome provide another critical source of infor-
mation about viral replication and the selective
pressures at work.
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Given the ongoing generation of HIV-1
sequence information and the dynamic nature
of viral populations, this virus will continue to
provide the basis for studies of viral evolution
and evolution in general. Deep sequencing
strategies will reveal features of the viral popu-
lation that have previously been hidden. There
will be continuing efforts to define selective
pressures in the context of sequence changes,
thus providing a link between the selective pres-
sure and the affected viral protein. Viral dynam-
ics and evolution will continue to be central
tools as our understanding of HIV-1 deepens.
The lessons learned to date provide the founda-
tion for continuing studies of virus–host inter-
actions and for efforts to develop strategies to
eradicate the virus completely.
REFERENCES
Reference is also in this collection.
 Arts EJ, Hazuda DJ. 2011. HIV-1 antiretroviral drug therapy.
Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.
a007161.
Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-
Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, et al.
2006. Residual human immunodeficiency virus type 1
viremia in some patients on antiretroviral therapy is
dominated by a small number of invariant clones rarely
found in circulating CD4þ T cells. J Virol 80: 6441–6457.
Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puer-
tas MC, Gatell JM, Domingo P, Paredes R, Sharkey M,
et al. 2011. HIV-1 replication and immune dynamics
are affected by raltegravir intensification of HAART-
suppressed subjects. Nat Med 16: 460–465.
Chersich MF, Gray GE. 2005. Progress and emerging chal-
lenges in preventing mother-to-child transmission.
Curr Infect Dis Rep 7: 393–400.
Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Tay-
lor H, Hermankova M, Chadwick K, Margolick J, Quinn
TC, et al. 1997. Quantification of latent tissue reservoirs
and total body viral load in HIV-1 infection. Nature
387: 183–188.
Coffin JM. 1995. HIV population dynamics in vivo: Impli-
cations for genetic variation, pathogenesis, and therapy.
Science 267: 483–488.
 Craigie R, Bushman FD. 2011. HIV DNA integration. Cold
Spring Harb Perspect Med doi: 10.1101/cshperspect.
a006890.
Davenport MP, Petravic J. 2010. CD8þ T cell control of
HIV—A known unknown. PLoS Pathog 6: e1000728.
doi: 10.1371/journal.ppat.1000728.
Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ,
Cranmer L, O’Shea A, Callender M, Spivak A, Brennan
T, et al. 2009. Treatment intensification does not reduce
residual HIV-1 viremia in patients on highly active anti-
retroviral therapy. Proc Natl Acad Sci 106: 9403–9408.
Fauci AS, Desrosiers RC. 1997. Pathogenesis of HIVand SIV.
In Retroviruses (ed. Coffin JM, et al.), pp. 587–635.
Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY.
Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM,
Dykes C, Bastow B, Para M, Lai J, Siliciano RF, et al.
2010. No evidence for decay of the latent reservoir in
HIV-1-infected patients receiving intensive enfuvirtide-
containing antiretroviral therapy. J Infect Dis 201:
293–296.
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM,
Markowitz M. 1995. Rapid turnover of plasma virions
and CD4 lymphocytes in HIV infection. Nature 373:
123–126.
 Hu WS, Hughes SH. 2011. HIV-1 reverse transcription. Cold
Spring Harb Perspect Med doi: 10.1101/cshperspect.
a006882.
Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard
J, Irwin CE, Safrit JT, Mittler J, Weinberger L, et al. 1999.
Dramatic rise in plasma viremia after CD8þ T cell deple-
tion in simian immunodeficiency virus-infected ma-
caques. J Exp Med 189: 991–998.
Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, Hir-
schel B, Weber R, Trkola A, Gunthard HF. 2008. HIV
rebounds from latently infected cells, rather than from
continuing low-level replication. Proc Natl Acad Sci
105: 16725–16730.
Josefsson L, King MS, Makitalo B, Brannstrom J, Shao W,
Maldarelli F, Kearney MF, Hu WS, Chen J, Gaines H,
et al. 2011. Majority of CD4þ T cells from peripheral
blood of HIV-1-infected individuals contain only one
HIV DNA molecule. Proc Natl Acad Sci 108: 11199–
11204.
Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer
U, Meese E, Wain-Hobson S, Meyerhans A. 2002. Recom-
bination: Multiply infected spleen cells in HIV patients.
Nature 418: 144.
 Karn J, Stoltzfus CM. 2011. Transcriptional and post-tran-
scriptional regulation of HIV-1 gene expression. Cold
Spring Harb Perspect Med doi: 10.1101/cshperspect.
a006916.
Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES,
Mellors JW, Rao V, Coffin JM, Palmer S. 2009. Human
immunodeficiency virus type 1 population genetics and
adaptation in newly infected individuals. J Virol 83:
2715–2727.
Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham
KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al.
2008. Identification and characterization of transmitted
and early founder virus envelopes in primary HIV-1
infection. Proc Natl Acad Sci 105: 7552–7557.
Kitrinos KM, Nelson JA, Resch W, Swanstrom R. 2005.
Effect of a protease inhibitor-induced genetic bottleneck
on human immunodeficiency virus type 1 env gene pop-
ulations. J Virol 79: 10627–10637.
Klatt NR, Shudo E, Ortiz AM, Engram JC, Paiardini M, Law-
son B, Miller MD, Else J, Pandrea U, Estes JD, et al. 2010.
CD8þ lymphocytes control viral replication in SIV-
mac239-infected rhesus macaques without decreasing
J. Coffin and R. Swanstrom



















the lifespan of productively infected cells. PLoS Pathog 6:
e1000747.
Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir
C, Detours V. 2001. Evolutionary and immunological
implications of contemporary HIV-1 variation. Br Med
Bull 58: 19–42.
Kuiken C, Korber B, Shafer RW. 2003. HIV sequence data-
bases. AIDS Rev 5: 52–61.
 Lackner AA, Lederman MM, Rodriguez B. 2011. HIV
pathogenesis—The host. Cold Spring Harb Perspect Med
doi: 10.1101/cshperspect.a007005.
Maldarelli F. 2011. Targeting viral reservoirs: Ability of anti-
retroviral therapy to stop viral replication. Curr Opin HIV
AIDS 6: 49–56.
Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA,
Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R,
et al. 2007. ARTsuppresses plasma HIV-1 RNA to a stable
set point predicted by pretherapy viremia. PLoS Pathog 3:
e46. doi: 10.1371/journal.ppat.0030046.
 Malim MH, Bieniasz PD. 2011. HIV restriction factors and
mechanisms of evasion. Cold Spring Harb Perspect Med
doi: 10.1101/cshperspect.a006940.
Mansky LM, Temin HM. 1995. Lower in vivo mutation rate
of human immunodeficiency virus type 1 than that
predicted from the fidelity of purified reverse transcrip-
tase. J Virol 69: 5087–5094.
McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M,
Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C,
et al. 2010. Short-course raltegravir intensification does
not reduce persistent low-level viremia in patients with
HIV-1 suppression during receipt of combination antire-
troviral therapy. Clin Infect Dis 50: 912–919.
Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA,
Kingsley LA. 1996. Prognosis in HIV-1 infection pre-
dicted by the quantity of virus in plasma. Science 272:
1167–1170.
Mens H, Kearney M, Wiegand A, Shao W, Schonning K,
Gerstoft J, Obel N, Maldarelli F, Mellors JW, Benfield T,
et al. 2010. HIV-1 continues to replicate and evolve in
patients with natural control of HIV infection. J Virol
84: 12971–12981.
Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda
DJ, Nguyen BY, Teppler H, Cooper DA. 2007. Antiretro-
viral therapy with the integrase inhibitor raltegravir alters
decay kinetics of HIV, significantly reducing the second
phase. AIDS 21: 2315–2321.
Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM,
Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, et al.
2003. New real-time reverse transcriptase-initiated PCR
assay with single-copy sensitivity for human immunode-
ficiency virus type 1 RNA in plasma. J Clin Microbiol 41:
4531–4536.
Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ,
Bazmi H, Rock D, Falloon J, Davey RT Jr, Dewar RL,
et al. 2005. Multiple, linked human immunodeficiency
virus type 1 drug resistance mutations in treatment-expe-
rienced patients are missed by standard genotype analy-
sis. J Clin Microbiol 43: 406–413.
Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ,
Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS.
2008. Low-level viremia persists for at least 7 years in
patients on suppressive antiretroviral therapy. Proc Natl
Acad Sci 105: 3879–3884.
Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Sak-
sela K, Markowitz M, Ho DD. 1997. Decay characteristics
of HIV-1-infected compartments during combination
therapy. Nature 387: 188–191.
Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid
evolution of the neutralizing antibody response to HIV
type 1 infection. Proc Natl Acad Sci 100: 4144–4149.
Rouzine IM, Coffin JM. 2005. Evolution of human immu-
nodeficiency virus under selection and weak recombina-
tion. Genetics 170: 7–18.
Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N,
Ashworth R, Gange S, Quinn TC, Siliciano RF, et al.
2002. Persistence of wild-type virus and lack of tem-
poral structure in the latent reservoir for human im-
munodeficiency virus type 1 in pediatric patients with
extensive antiretroviral exposure. J Virol 76: 9481–
9492.
Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA,
Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon
BJ, et al. 1999. Control of viremia in simian immunode-
ficiency virus infection by CD8þ lymphocytes. Science
283: 857–860.
Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG,
Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn
GH, He X, et al. 1999. Consistent viral evolutionary
changes associated with the progression of human
immunodeficiency virus type 1 infection. J Virol 7312:
10489–10502.
Sharkey ME, Stevenson M. 2001. Two long terminal repeat
circles and persistent HIV-1 replication. Curr Opin Infect
Dis 14: 5–11.
 Shaw GM, Hunter E. 2011. HIV transmission. Cold Spring
Harb Perspect Med doi: 10.1101/cshperspect.a006965.
Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Balti-
more D. 2011. Cell-to-cell spread of HIV permits
ongoing replication despite antiretroviral therapy. Nature
477: 95–98.
 Siliciano RF, Greene WC. 2011. HIV latency. Cold Spring
Harb Perspect Med doi: 10.1101/cshperspect.a007096.
Svarovskaia ES, Cheslock SR, Zhang WH, Hu WS, Pathak
VK. 2003. Retroviral mutation rates and reverse tran-
scriptase fidelity. Front Biosci 8: D117–D134.
 Swanstrom R, Coffin J. 2011. HIV-1 pathogenesis: The virus.
Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.
a007443.
Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ,
McKernan JL, Pawluk DM, Mohan KM, Lewis PF, Mul-
lins JI, et al. 2005. Evidence that low-level viremias during
effective highly active antiretroviral therapy result from
two processes: Expression of archival virus and replica-
tion of virus. J Virol 79: 9625–9634.
 Walker B, McMichael A. 2011. The T-cell response to HIV.
Cold Spring Harb Perspect Med doi: 10.1101/cshper
spect.a007054.
Wei X, Ghosh S, Taylor ME, Johnson VA, Emini EA, Deutsch
P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al.
1995. Viral dynamics in human immunodeficiency virus
type 1 infection. Nature 373: 117–122.
HIV Pathogenesis: Viral Populations and Infected Cells



















Wong JK, Strain MC, Porrata R, Reay E, Sankaran-Walters S,
Ignacio CC, Russell T, Pillai SK, Looney DJ, Dandekar S.
2010. In vivo CD8þ T-cell suppression of siv viremia is
not mediated by CTL clearance of productively infected
cells. PLoS Pathog 61: e1000748.
Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M,
Lewin S, Talal A, Racz P, Perelson AS, Korber BT, et al.
1999. Quantifying residual HIV-1 replication in patients
receiving combination antiretroviral therapy. N Engl J
Med 340: 1605–1613.
J. Coffin and R. Swanstrom
16 Cite this article as Cold Spring Harb Perspect Med 2013;3:a012526
w
w
w
.p
er
sp
ec
ti
ve
si
n
m
ed
ic
in
e.
o
rg
